Bendamustine in the treatment of chronic lymphocytic leukemia

被引：15

作者：

Knaulf, Wolfgang ^{[1
]}

机构：

[1] Onkol Gemeinschaftspraxis, D-60389 Frankfurt, Germany

来源：

EXPERT REVIEW OF ANTICANCER THERAPY | 2009年 / 9卷 / 02期

关键词：

alkylating agent; antimetabolite; bendamustine; chemotherapy; chronic lymphocytic leukemia; FLUDARABINE PLUS CYCLOPHOSPHAMIDE; RANDOMIZED PHASE-III; EVERY; 3; WEEKS; IN-VITRO; 1ST-LINE THERAPY; INITIAL THERAPY; CHLORAMBUCIL; PREDNISONE; RITUXIMAB; CANCER;

D O I：

10.1586/14737140.9.2.165

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Bendamustine is a cytotoxic agent that combines alkylating and antimetabolite effects. It has shown promising efficacy in a number of hematological cancers and, hence, is being investigated in patients with chronic lymphocytic leukemia (CLL), which is the most common form of adult leukemia in the Western world. Phase I/II trials with bendamustine as single-agent therapy in CLL have shown overall response rates of 56-93% and complete response rates of 7-29%. Preliminary data from a Phase III trial comparing bendamustine and chlorambucil (an agent widely used in the current treatment of CLL) have shown significantly higher response rates with bendamustine. Bendamustine has also shown activity in CLL when combined with mitoxantrone, rituximab or both. The principal toxicities associated with bendamustine are hernatological, mainly leukopenia.

引用

页码：165 / 174

页数：10

共 44 条

[1] Bendamustine in the treatment of chronic lymphocytic leukemia: Results and future perspectives [J].

Aivado, M ;

Schulte, K ;

Henze, L ;

Burger, J ;

Finke, J ;

Haas, R .

SEMINARS IN ONCOLOGY, 2002, 29 (04) :19-22

[2]

[Anonymous], BLOOD

[3]

Bergmann MA, 2005, HAEMATOLOGICA, V90, P1357

[4]

BINET JL, 1981, CANCER-AM CANCER SOC, V48, P198, DOI 10.1002/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO

[5]

2-V

[6] High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas [J].

Bremer, K .

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2002, 128 (11) :603-609

[7] Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial [J].

Catovsky, D. ;

Richards, S. ;

Matutes, E. ;

Oscier, D. ;

Dyer, M. J. S. ;

FBezares, R. ;

Pettitt, A. R. ;

Hamblin, T. ;

Milligan, D. W. ;

Child, J. A. ;

Hamilton, M. S. ;

Dearden, C. E. ;

Smith, A. G. ;

Bosanquet, A. G. ;

Davis, Z. ;

Brito-Babapulle, V. ;

Else, M. ;

Wade, R. ;

Hillmen, P. .

LANCET, 2007, 370 (9583) :230-239

[8] Metabolic profile of [14C] bendamustine in rat urine and bile:: Preliminary structural identification of metabolites [J].

Chovan, James P. ;

Li, Feng ;

Yu, Erya ;

Ring, Steven C. .

DRUG METABOLISM AND DISPOSITION, 2007, 35 (10) :1744-1753

[9]

Chow KU, 2002, HAEMATOLOGICA, V87, P33

[10] Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia [J].

Eichhorst, BF ;

Busch, R ;

Hopfinger, G ;

Pasold, R ;

Hensel, M ;

Steinbrecher, C ;

Siehl, S ;

Jäger, U ;

Bergmann, M ;

Stilgenbauer, S ;

Schweighofer, C ;

Wendtner, CM ;

Döhner, H ;

Brittinger, G ;

Emmerich, B ;

Hallek, M .

BLOOD, 2006, 107 (03) :885-891

← 1 2 3 4 5 →